公开(公告)号：WO2007070509A3

公开(公告)日：2008-07-03

申请号：PCT/US2006047357

申请日：2006-12-12

Applicant: UNIV PITTSBURGH ,  BURNS JAMES BRIAN ,  CARATTINO MARCELO DANIEL ,  HUGHEY REBECCA PREVOST ,  KLEYMAN THOMAS RALPH ,  SHENG SHAOHU

Inventor： BURNS JAMES BRIAN ,  CARATTINO MARCELO DANIEL ,  HUGHEY REBECCA PREVOST ,  KLEYMAN THOMAS RALPH ,  SHENG SHAOHU

IPC: A61K38/00 ,  C07K7/00

CPC classification number: C07K14/705 ,  A61K38/00

Abstract: Disclosed herein are peptide cleavage products, generated during natural processing of epithelial sodium channel a- and ?-subunits and their use in inhibiting epithelial sodium channel activity. Also disclosed herein are polypeptide and polypeptide analog derivatives of those agents. These epithelial sodium channel-inhibitory agents may be formulated into a drug product for, without limitation, inhibition of epithelial sodium channel function in a patient's airway, useful in treating, among other diseases or conditions: hypertension, congestive heart failure, cirrhosis, nephrotic syndrome, hypokalemia, cystic fibrosis, chronic pulmonary obstructive diseases, such as chronic bronchitis, asthma and bronchiectasis. A method of testing the activity of an epithelial sodium channel-inhibitory agent also is provided.

Abstract translation: 本文公开了在上皮钠通道α-和β-亚基的天然加工期间产生的肽切割产物及其在抑制上皮钠通道活性中的用途。 本文还公开了那些试剂的多肽和多肽类似物衍生物。 这些上皮钠通道抑制剂可以配制成药物产品，用于但不限于抑制患者气道中的上皮钠通道功能，其可用于治疗其它疾病或病症：高血压，充血性心力衰竭，肝硬化，肾病综合征 ，低钾血症，囊性纤维化，慢性肺动脉阻塞性疾病，如慢性支气管炎，哮喘和支气管扩张。 还提供了测试上皮钠通道抑制剂的活性的方法。

公开(公告)号：WO2007070509A2

公开(公告)日：2007-06-21

申请号：PCT/US2006/047357

申请日：2006-12-12

Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  BURNS, James, Brian ,  CARATTINO, Marcelo, Daniel ,  HUGHEY, Rebecca, Prevost ,  KLEYMAN, Thomas, Ralph ,  SHENG, Shaohu

Inventor： BURNS, James, Brian ,  CARATTINO, Marcelo, Daniel ,  HUGHEY, Rebecca, Prevost ,  KLEYMAN, Thomas, Ralph ,  SHENG, Shaohu

IPC: A61K38/17 ,  C07K14/47

CPC classification number: C07K14/705 ,  A61K38/00

Abstract: Disclosed herein are peptide cleavage products, generated during natural processing of epithelial sodium channel α- and γ-subunits and their use in inhibiting epithelial sodium channel activity. Also disclosed herein are polypeptide and polypeptide analog derivatives of those agents. These epithelial sodium channel-inhibitory agents may be formulated into a drug product for, without limitation, inhibition of epithelial sodium channel function in a patient's airway, useful in treating, among other diseases or conditions: hypertension, congestive heart failure, cirrhosis, nephrotic syndrome, hypokalemia, cystic fibrosis, chronic pulmonary obstructive diseases, such as chronic bronchitis, asthma and bronchiectasis. A method of testing the activity of an epithelial sodium channel-inhibitory agent also is provided.

Abstract translation: 本文公开了在上皮钠通道α-和β-亚基的天然加工期间产生的肽切割产物及其在抑制上皮钠通道活性中的用途。 本文还公开了那些试剂的多肽和多肽模拟衍生物。 这些上皮钠通道抑制剂可以配制成药物产品，用于但不限于抑制患者气道中的上皮钠通道功能，其可用于治疗其它疾病或病症：高血压，充血性心力衰竭，肝硬化，肾病综合征 ，低钾血症，囊性纤维化，慢性肺动脉阻塞性疾病，如慢性支气管炎，哮喘和支气管扩张。 还提供了测试上皮钠通道抑制剂活性的方法。